LL-37

Redness, itching and swelling are the most common reactions in user and vendor reports, and users usually describe them fading within a few hours. In lab studies LL-37 draws immune cells to where it's applied, so some local inflammation is plausible. The reaction doesn't show the peptide is working, though: irritation and impurities can cause the same signs. Some users also describe body aches and fever within hours of injecting. No trial has tested subcutaneous LL-37, so there's no controlled data on how often these reactions happen.

It's a host defense peptide, not an approved antibiotic. In lab studies it kills a broad range of bacteria, viruses and fungi by disrupting their membranes, a different mode of action from most conventional antibiotics. It hasn't been shown to treat any infection in people. As of October 2026, it isn't approved as a drug anywhere.

Long-term safety is unknown, and no data support continuous use. No human study has given LL-37 by injection for any length of time; the longest controlled exposure was the topical Phase IIb, with up to 13 weeks of treatment on leg ulcers. FDA notes nonclinical findings that suggest harm to male reproduction and tumor-promoting effects in some tissues, and lab studies link excess LL-37 to inflammatory skin disease. Vendor and community protocols describe short cycles of 2-4 weeks, but that duration hasn't been tested.

Users who pair them often describe LL-37 as the 'first responder' against infection and BPC-157 as the repair peptide. That division rests on lab and animal mechanisms, not on any study that compared or combined them. Most BPC-157 data come from rodents, with three small uncontrolled human pilots. LL-37's only controlled human trial, a topical leg-ulcer study, missed its primary endpoint. As of October 2026, neither is approved as a drug.